Literature DB >> 20494436

JUPITER, rosuvastatin, and the European Medicines Agency.

Paul M Ridker, Robert J Glynn.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20494436     DOI: 10.1016/S0140-6736(10)60760-X

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  4 in total

Review 1.  Preventing the aortic complications of Marfan syndrome: a case-example of translational genomic medicine.

Authors:  Alain Li-Wan-Po; Bart Loeys; Peter Farndon; David Latham; Caroline Bradley
Journal:  Br J Clin Pharmacol       Date:  2011-07       Impact factor: 4.335

2.  P-selectin glycoprotein ligand-1 deficiency leads to cytokine resistance and protection against atherosclerosis in apolipoprotein E deficient mice.

Authors:  Wei Luo; Hui Wang; Miina K Ohman; Chiao Guo; Kate Shi; Julia Wang; Daniel T Eitzman
Journal:  Atherosclerosis       Date:  2011-10-17       Impact factor: 5.162

3.  C-reactive protein levels in patients at cardiovascular risk: EURIKA study.

Authors:  Julian P J Halcox; Carine Roy; Florence Tubach; José R Banegas; Jean Dallongeville; Guy De Backer; Eliseo Guallar; Ogün Sazova; Jesús Medina; Joep Perk; Philippe Gabriel Steg; Fernando Rodríguez-Artalejo; Claudio Borghi
Journal:  BMC Cardiovasc Disord       Date:  2014-02-24       Impact factor: 2.298

4.  Prevention of cardiovascular disease guided by total risk estimations--challenges and opportunities for practical implementation: highlights of a CardioVascular Clinical Trialists (CVCT) Workshop of the ESC Working Group on CardioVascular Pharmacology and Drug Therapy.

Authors:  Faiez Zannad; Jean Dallongeville; Robert J Macfadyen; Luis M Ruilope; Lars Wilhelmsen; Guy De Backer; Ian Graham; Matthias Lorenz; Giuseppe Mancia; David A Morrow; Zeljko Reiner; Wolfgang Koenig
Journal:  Eur J Prev Cardiol       Date:  2012-12       Impact factor: 7.804

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.